Early safety check for new drug in people with liver issues
NCT ID NCT04819464
Summary
This early-stage study tested how a single dose of an experimental drug called cenerimod is processed by the body in people with mild or moderate liver impairment, compared to healthy volunteers. The main goal was to understand if liver problems change how the drug moves through the body and to check for safety. The study involved 24 participants and did not aim to treat any disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BlueClinical Phase 1 Hospital de Prelado
Porto, 4250-449, Portugal
-
CRU Hungary
Kistarcsa, H2143, Hungary
Conditions
Explore the condition pages connected to this study.